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Abstract
Background: Autologous chondrocyte implantation (ACI) has a failure rate of approximately 20%, but it is yet to be
fully understood why. Biomarkers are needed that can pre-operatively predict in which patients it is likely to fail, so
that alternative or individualised therapies can be offered. We previously used label-free quantitation (LF) with a dynamic
range compression proteomic approach to assess the synovial fluid (SF) of ACI responders and non-responders. However,
we were able to identify only a few differentially abundant proteins at baseline. In the present study, we built upon these
previous findings by assessing higher-abundance proteins within this SF, providing a more global proteomic analysis on
the basis of which more of the biology underlying ACI success or failure can be understood.
Methods: Isobaric tagging for relative and absolute quantitation (iTRAQ) proteomic analysis was used to assess SF from
ACI responders (mean Lysholm improvement of 33; n = 14) and non-responders (mean Lysholm decrease of 14; n= 13) at
the two stages of surgery (cartilage harvest and chondrocyte implantation). Differentially abundant proteins in iTRAQ and
combined iTRAQ and LF datasets were investigated using pathway and network analyses.
Results: iTRAQ proteomic analysis confirmed our previous finding that there is a marked proteomic shift in response to
cartilage harvest (70 and 54 proteins demonstrating ≥ 2.0-fold change and p < 0.05 between stages I and II in responders
and non-responders, respectively). Further, it highlighted 28 proteins that were differentially abundant between
responders and non-responders to ACI, which were not found in the LF study, 16 of which were altered at baseline. The
differential expression of two proteins (complement C1s subcomponent and matrix metalloproteinase 3) was confirmed
biochemically. Combination of the iTRAQ and LF proteomic datasets generated in-depth SF proteome information that
was used to generate interactome networks representing ACI success or failure. Functional pathways that are
dysregulated in ACI non-responders were identified, including acute-phase response signalling.
Conclusions: Several candidate biomarkers for baseline prediction of ACI outcome were identified. A holistic overview of
the SF proteome in responders and non-responders to ACI has been profiled, providing a better understanding of the
biological pathways underlying clinical outcome, particularly the differential response to cartilage harvest in non-
responders.
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Background
Identification of putative biomarkers that can be used to
predict patient outcome prior to treatment for cartilage
injury has been highlighted as a key initiative for the preven-
tion of osteoarthritis (OA) by the Osteoarthritis Research
Society International [1]. Further, in the United Kingdom,
the National Health Service has increased the need to
identify accurate prognostic biomarkers for application of
the recent National Institute for Health and Care Excellence
(NICE) recommendation for use of the cell therapy called
autologous chondrocyte implantation (ACI) [2].
We recently published the first study [3], to our know-
ledge, in which a proteomic approach has been used with
the aim of identifying candidate biomarkers to predict the
success of ACI, a cellular therapy for the treatment of
traumatic cartilage injury [4, 5]. This therapy is composed
of a two-stage procedure: During the initial surgery (stage
I), healthy cartilage is harvested from a minor load-bearing
region of the joint, then chondrocytes are isolated and
culture is expanded for 3–4 weeks prior to a second surgery
(stage II), in which the chondrocytes are implanted into the
cartilage defect [5, 6]. Approximately 500 patients have
been treated with ACI in our centre, and despite an 81%
success rate [7], we have yet to fully understand why some
individuals do not respond well. We have identified a bio-
marker, aggrecanase-1, that, when its activity is undetect-
able pre-operatively, can be used together with known
demographic and injury-associated risk factors to help pre-
dict ACI success [8, 9]. However, we have yet to identify a
biomarker (or panel of biomarkers) that can be used to
accurately predict ACI failure. The identification of such a
biomarker(s) for ACI and other cartilage repair strategies
would allow for the better stratification of patients prior to
joint surgery and may provide candidates for therapies to
improve ACI success.
Proteomic analyses remain one of the most widely
used methods to identify novel biomarker candidates
and have previously been used to identify biomarkers of
OA progression (as summarised by Hsueh et al. in 2014
[10]). The synovial fluid (SF) provides an attractive bio-
logical fluid for biomarker identification because it
bathes the injured joint and therefore contains proteins
that might reflect the whole joint environment. Prote-
omic profiling of the SF, however, is technically difficult
owing to the broad dynamic range of proteins present
within it [7, 8]. Several unbiased global proteomic stud-
ies aimed at the identification of biomarkers within the
SF have been completed. Nevertheless, the number of
protein ‘hits’ has been somewhat limited, because
researchers either have tended to profile SF with no
pre-treatment to account for the wide range of proteins
[11–16] or have depleted high-abundance proteins
[17–22], meaning that the altered quantities of these
proteins cannot be considered.
Isobaric tags for absolute and relative quantitation
(iTRAQ) is reported to be the most accurate labelling
method for quantifying comparative abundance of pro-
teins [23]. When compared with label-free quantitation
(LF) proteomics, iTRAQ quantitation has traditionally
been considered a more accurate technique [24];
however, as mass spectrometers are improved, these
techniques are becoming more comparable, and LF is
becoming increasingly popular [25]. Unlike LF proteo-
mics, iTRAQ uses isobaric tags to label the primary
amines at the peptide level prior to pooling the samples
to enable simultaneous identification and quantitation of
the proteins. Fourplex and eightplex labels are available,
enabling quantitation of up to eight conditions in a
single analysis, thus minimising the number of mass
spectrometry runs that can be cost-effective and time-
efficient. However, when compared with LF, in which
any number of samples can be analysed and compared,
iTRAQ labelling limits the number of samples that can
be compared, meaning biological replicate samples are
often pooled together into relevant biological conditions.
iTRAQ proteomics is a commonly used tool for the
identification of biomarkers in a plethora of diseases.
This proteomic approach has been used to profile the SF
proteome [20, 26], successfully identifying differentially
abundant protein biomarker candidates for several
diseases/conditions.
Our previous study highlighted the potential of using
protein equalisation to study low-abundance proteins in
human SF, but this identified few differentially abundant
proteins in baseline SF, when comparing individuals who
did or did not do well following cartilage repair therapy
[1]. The aim of the present study therefore was to
increase the number of protein biomarker candidates
that could be identified for the pre-operative prediction
of clinical outcome following ACI and to allow for the
assessment of high-abundance proteins that may also
strengthen the understanding of the biological processes
underlying treatment success.
Methods
SF collection and storage
SF was collected as described previously [3, 8, 27] from
the knee joints of patients who provided informed
consent and following local research ethics committee
approval. Immediately prior to both ACI surgeries, stage
I (cartilage harvest) and stage II (chondrocyte implant-
ation), 20 ml of saline was injected into the joint and 20
rounds of leg flexion and extension were carried out to
allow aspiration of as much SF as possible [3, 27]. SF
was then centrifuged at 6000 × g for 15 minutes at 4 °C
and split into aliquots for long-term storage in liquid ni-
trogen. The dilution factor of the SF samples was calcu-
lated by comparing urea content in SF with matched
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blood plasma using a QuantiChrom™ Urea Assay Kit
(BioAssay Systems, Hayward, CA, USA) according to
the manufacturer’s instructions and as described previ-
ously [3, 8, 28], and SF samples with a dilution factor >
10 were excluded from the study.
Clinical responders to ACI were defined as individuals
who demonstrated a Lysholm score increase of ≥ 10
points at 12 months post-treatment compared with their
baseline score, as has been used previously [29–31]. The
Lysholm score is a validated [32] patient-self assessment
score encompassing knee pain and joint function that
ranges from 0 to 100, with 100 representing ‘perfect’
knee function [32, 33]. Thirteen patients were consid-
ered as non-responders to ACI, demonstrating a mean
decrease in Lysholm score of 14 points (range − 4 to −
46), and 14 SF donors were considered responders with
a mean improvement of 33 points (range 17–54).
Sample preparation and analysis using iTRAQ proteomics
(iTRAQ nanoLC-MS/MS)
Total protein was quantified using a Pierce™ 660 nm Pro-
tein Assay (Thermo Fisher Scientific, Hemel Hempstead,
UK) [34], and a total of 200 μg of SF protein was pooled
equally from the donors in each of the following experi-
mental groups: stage I responders (n = 8), stage I non-
responders (n = 7), stage II responders (n = 12), and stage
II non-responders (n = 12) (Table 1). The pooled samples
were then precipitated in six volumes of ice-cold acetone
overnight at − 20 °C. The precipitates were pelleted by
centrifugation at 13,000 × g for 10 minutes at 4 °C before
being re-suspended in 200 μl of triethylammonium bicar-
bonate buffer. Eighty-five micrograms of protein for each
experimental sample were then subjected to reduction, al-
kylation (as instructed in the iTRAQ labelling kit; Applied
Biosystems, Bleiswijk, The Netherlands). Sequencing
Grade Modified Trypsin (10 μg/85 μg of protein; Pro-
mega, Madison, WI, USA) was then added to the samples
for overnight digestion at 37 °C. Tryptic digests were la-
belled with the iTRAQ tags according to the manufac-
turer’s instructions before being pooled into one
microcentrifuge tube prior to being dried in a vacuum
centrifuge: 114 tag- stage II responders, 115 tag- stage II
non-responders, 116 tag- stage I responders and 117 tag-
stage I non-responders.
iTRAQ-labelled peptides were resuspended in 0.6 ml of
loading buffer (10 mM monopotassium phosphate
[KH2PO4], 20% acetonitrile [MeCN], pH 3.0), followed by
sonication. The pH was adjusted to 3.0 with 0.5 M ortho-
phosphoric acid (H3PO4). The peptides were separated by
strong cation exchange chromatography (SCX) as described
previously [35]. A total of 14 SCX fractions were analysed
by nano-electrospray ionisation-LC-MS/MS using a Triple-
TOF 5600 tandem mass spectrometer (AB Sciex, Framing-
ham, MA, USA) as described previously [36].
The raw mass spectrometry data file was subsequently
analysed using ProteinPilot 4.5 software with the Paragon™
Table 1 Demographic data for patient participants whose samples from Stage I or Stage II were analysed who responded clinically
(responders) or who did not respond (non-responders) to autologous chondrocyte implantation (ACI)
Stage I Stage II Mann-Whitney U test
p value
(A)R v NR- SI; (B)
R v NR- SI
Mann-Whitney U test
p value)
(A)SI v SII-R; (B)
SI v SII- NR
Responders
(n = 8)
Non-responders
(n = 7)
Responders
(n = 12)
Non-responders
(n = 12)
Difference in Lysholm score 27 (17–38) − 8 (− 4 to − 17) 34 (17–54) − 11 (− 4 to − 46) (A) 0.0003; (B) < 0.0001 (A) 0.21; (B) 0.55
BMI, kg/m2 29 (23–31) 27 (24–31) 27 (23–48) 29 (22–36) (A) 0.94; (B) 0.54 (A) 0.73; (B) 0.68
Age, years 32 (17–49) 40 (25–50) 40 (17–90) 43 (25–52) (A) 0.28; (B) 0.92 (A) 0.17; (B) 0.58
Male/female sex, n 8/0 7/0 11/1 10/2 (A) > 0.99; (B) > 0.99 (A) > 0.99; (B) 0.51
Smoker, n 1 2 1 3 (A) 0.54; (B) 0.59 (A) > 0.99; (B) > 0.99
Dilution factor of SF 5 (3–9) 4 (2–7) 4 (1–9) 3 (2–5) (A) 0.48; (B) 0.25 (A) 0.53; (B) 0.50
Total defect area, cm2 14 (0.4–24) 6 (0.6–12) 6 (1–20) 5 (0.6–12) (A) 0.74; (B) 0.35 (A) 0.45; (B) 0.28
Patella defect, n 1 1 4 2 (A) > 0.99; (B) 0.64 (A) 0.60; (B) > 0.99
LFC defect, n 2 0 0 0 (A) 0.47; (B) > 0.99 (A) 0.15; (B) > 0.99
LTP defect, n 1 0 0 0 (A) > 0.99; (B) > 0.99 (A) 0.15; (B) > 0.99
MFC defect, n 2 2 1 6 (A) > 0.99; (B) 0.07 (A) 0.54; (B) 0.63
Trochlea defect, n 0 3 2 1 (A) 0.20; (B) > 0.99 (A) 0.49; (B) 0.12
Multiple defects, n 1 0 1 1 (A) > 0.99; (B) > 0.99 (A) > 0.99; (B) > 0.99
Unknown defect location, n 1 1 4 2 (A) > 0.99; (B) 0.64 (A) 0.60; (B) > 0.99
Footnote: None of the demographic parameters, other than a difference in Lysholm score, showed differences between responders (R) and non-responders (NR)
among individuals whose SF from stage I (SI) or stage II (SII) was compared, nor were there differences between individuals who were either responders or non-
responders when we compared stage I and stage II samples (p ≥ 0.05 by Mann-Whitney U test). Data are median (range). Abbreviations: BMI Body mass index, LFC
Lateral femoral condyle, LTP Lateral tibial plateau, MFC Medial femoral condyle
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and ProGroup™ algorithms (AB Sciex) against the human
sequences in the UniProtKB/Swiss-Prot database (down-
loaded in December 2012). Searches were performed
using the pre-set iTRAQ settings in ProteinPilot. Trypsin
was selected as the cleavage enzyme and methyl metha-
nethiosulphonate for the modification of cysteines with a
‘thorough ID’ search effort. ProteinPilot’s bias correction
assumes that most proteins do not change in expression.
Finally, detected proteins were reported with a protein
threshold [unused ProtScore (confidence)] > 0.05 and used
in the quantitative analysis if they were identified with two
or more unique peptides with 95% confidence or above. p
Values and false discovery rates for the iTRAQ ratios were
calculated using the ProteinPilot software. Proteins with
iTRAQ ratios with p values ≤ 0.05 and with differential
abundance of greater than or equal to ± 2.0-fold change
(FC) were used in further analysis.
Verification of iTRAQ nanoLC-MS/MS results using
enzyme linked immunosorbent assay
Two proteins of biological relevance were measured by
enzyme-linked immunosorbent assay (ELISA) in the non-
pooled samples to verify the MS findings. Firstly, comple-
ment C1S subcomponent (C1s) was selected because this
protein demonstrated differential abundance between re-
sponders and non-responders to ACI within the baseline SF
(prior to stage I surgery) and therefore could have potential
as a biomarker of outcome prediction. C1s was assessed
using a human ELISA (CUSABIO, Houston, TX, USA).
Samples were first assayed using a 1:100 dilution in assay
sample diluent, and for those samples that were undetect-
able in the assay, the assay was repeated using undiluted
samples. Secondly, matrix metalloproteinase 3 (MMP3) was
selected to investigate the differential response to stage I
surgery (i.e., the proteomic shift between stages I and II) in
non-responders to ACI. MMP3 was assessed using a human
Quantikine® ELISA (R&D Systems, Abingdon, UK). Samples
were diluted 1:100 in assay kit diluent prior to assessment.
Both ELISAs were carried out according to the
manufacturer’s instructions, and protein concentrations
were normalised to the sample dilution factor. Statistical
analysis was performed using Prism version 6.0 software
(GraphPad Software, La Jolla, CA, USA). Student’s t tests
were used to assess differential abundance.
Assessment of protein overlap identified using the two
proteomic approaches
To assess whether the use of two independent proteomic
approaches allows for a greater number of significant
protein changes to be identified, the datasets from this
study (iTRAQ nanoLC-MS/MS [nLC-MS/MS]) and our
previously published study assessing the same patient
samples (LF LC-MS/MS [3]) were compared with one an-
other. Venn diagrams were plotted using VENNY 2.1.0
software [37] to assess the overlap of differentially abun-
dant proteins that were identified via the two approaches.
Pathway and network analysis of proteomic datasets
The datasets generated using both proteomic approaches
were combined. Specifically, proteins that were differen-
tially expressed (≥ 1.2 FC; p ≤ 0.05) in each biological
comparison (e.g., stage I responders versus non-
responders) in either proteomic approach were merged
into a single dataset. A modest FC cutoff was used to
ensure that the greatest number of differentially abun-
dant proteins could be included in the pathway and net-
work analyses, as has been done previously [3, 18]. The
iTRAQ nLC-MS/MS dataset independently, as well as
when merged with the LF dataset, was analysed using
pathway enrichment analysis (Ingenuity Pathway
Analysis; Qiagen Bioinformatics, Redwood City, CA, US)
to identify and visualise affected canonical pathways.
Pathways with a significance level of p ≤ 0.005 were con-
sidered statistically significant (Fisher’s exact test).
The merged LF and iTRAQ nLC-MS/MS datasets of
proteomic response to cartilage harvest (e.g., differential
abundance between stages I and II) in responders and
non-responders were assessed using interactome net-
work analysis, which is an unbiased mathematical
method of visualising and interpreting complex interac-
tions between large numbers of molecules [38]. Interac-
tome networks are made up of nodes (the individual
objects being studied, such as proteins) and edges (the
connections between the objects, such as known
protein-protein interactions) [39]. By studying groups of
proteins that are highly interconnected, known as mod-
ules, key functions within an interactome network can
be highlighted [39]. Conducting interactome network
analysis alongside pathway enrichment analysis allows
for greater confidence in the selection of candidate path-
ways or molecules for further study, because these repre-
sent two independent methods of mapping the data:
known protein-protein interactions and text mining, re-
spectively. The interactions between the differentially
abundant proteins were assessed using the PINA4MS
(Protein Interaction Network Analysis For Multiple Sets)
app [40] in Cytoscape version 3.0 to generate network
models based on protein-protein interactions. These
models were based either on only those proteins identi-
fied in the proteomic analyses (non-inferred nodes) or
on proteins identified in the proteomic analyses along-
side their inferred interactions (inferred nodes) [41]. The
ModuLand (version 2.8.3) algorithm [42] was applied to
the interactome networks in Cytoscape version 3.0 to
identify highly connected clusters of proteins (modules)
that demarcate the hierarchical structure of the interac-
tome network. The biological function of each module
was assessed by analysing the proteins identified within
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each module using the pathway analysis tool in Reac-
tome software [43, 44]. The significance of the pathway
functions identified in Reactome was determined by
Fisher’s exact test, and p ≤ 0.05 was considered statisti-
cally significant.
Results
The proteomic data derived from this study have been
deposited in the PRoteomics IDEntifications (PRIDE)
ProteomeXchange and can be accessed using the identi-
fier [PXD008321].
Identification of proteins to predict ACI outcome prior to
stage I or stage II
iTRAQ nLC-MS/MS highlighted 16 proteins (greater than
or equal to ± 2.0 FC; p ≤ 0.05) that were differentially
abundant between responders and non-responders to ACI
at baseline (immediately prior to stage I) (Table 2). Prior
to stage II of the ACI procedure, 12 proteins displayed
differential abundance between responders and non-
responders (Table 3).
At both stages of treatment, SF analysed using iTRAQ
nLC-MS/MS identified a greater number of differentially
abundant proteins between individuals who did or did
not respond well to ACI compared with SF that had
undergone protein normalisation using the ProteoMi-
ner™ protein enrichment kit (Bio-Rad Laboratories,
Hercules, CA, USA) and LF LC-MS/MS analysis [3].
Further, the two proteomic techniques identified no
common differentially abundant proteins. The two pro-
teins selected and assessed by ELISA (C1s and MMP3)
could verify the iTRAQ nLC-MS/MS (Fig. 1).
Differential abundance of proteins at stage II compared
with stage I of ACI
Proteomic profiling of the SF using iTRAQ nLC-MS/MS
highlighted a considerable effect of the cartilage harvest
procedure (stage I) in both responders and non-
responders, with 70 and 54 proteins being differentially
abundant between stages I and II, respectively, thus
strengthening the similar findings derived from the ana-
lysis of these samples using LF LC-MS/MS [3]. Interest-
ingly, the iTRAQ nLC-MS/MS and LF LC-MS/MS
identified no common protein differences between stage
I and stage II in the clinical responders (70 differentially
abundant proteins identified by iTRAQ nLC-MS/MS
and 14 identified by LF LC-MS/MS) (Table 4). This lack
of overlap between the two proteomic techniques is
highlighted in Fig. 2. There were, however, six proteins
(gelsolin, vitamin K-dependent protein S, C4b-binding
protein alpha chain, fibrinogen alpha chain, fibrinogen
beta chain and fibrinogen gamma chain) that were iden-
tified by both proteomic techniques in the non-
responders, all of which showed commonality in the
Table 2 Fold change of proteins that are differentially abundant in the synovial fluid of clinical non-responders compared with clinical re-
sponders to autologous chondrocyte implantation (ACI) immediately prior to stage I
Protein Fold change Identification method
Description Accession no. LF LC-MS/MS iTRAQ nLC-MS/MS
Complement C1S subcomponent P09871 − 5.15 +
Haptoglobin P00738 − 4.49 +
Mesencephalic astrocyte-derived neurotrophic factor P55145 2.15 +
Plasma protease C1 inhibitor P05155 2.19 +
Immunoglobulin kappa chain V-II region MIL P01615 2.60 +
Bifunctional glutamate/proline-transfer RNA ligase P07814 2.61 +
Pigment epithelium-derived factor P36955 3.13 +
Apolipoprotein A-IV P06727 3.19 +
Apolipoprotein L1 O14791 3.19 +
N-acetylglucosamine-6-sulphatase P15586 3.25 +
Retinol-binding protein 4 P02753 3.34 +
Inter-alpha-trypsin inhibitor heavy chain H1 P19827 3.37 +
Extracellular matrix protein 1 Q16610 3.77 +
Lumican P51884 3.80 +
Histidine-rich glycoprotein P04196 3.84 +
Endoplasmin P14625 4.37 +
Serum paraoxonase/arylesterase 1 P27169 4.41 +
Footnote: Differential abundance was denoted by greater than or equal to ± 2.0-fold change; p ≤ 0.05; protein identified by at least two unique peptides. Positive
numbers denote higher abundance in non-responders than in responders. Proteins were identified using either protein dynamic compression coupled with label-free
quantitation LC-MS/MS or no protein dynamic compression with isobaric tags for absolute and relative quantitation (iTRAQ) LC-MS/MS
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direction of protein shift across the MS platforms, with
iTRAQ nLC-MS/MS consistently resulting in greater
differences in abundance than those identified from the
LF LC-MS/MS data. A total of 54 protein abundance
changes between stages I and II in non-responders were
identified using iTRAQ nLC-MS/MS, and 55 protein
differences were identified by LF LC-MS/MS (Table 5
and Fig. 2).
iTRAQ nLC-MS/MS confirmed a significant response to
cartilage harvest procedure (stage I) in nonresponders to ACI
Pathway analysis of the iTRAQ nLC-MS/MS-identified
proteins, using the pathway enrichment tools in Ingenu-
ity Pathway Analysis, suggested that the proteins which
were differentially abundant at stage II compared with
stage I in non-responders are likely to impact numerous
canonical pathways, many of which were confirmatory
of the previously published functional pathways identi-
fied from the LF nLC-MS/MS-derived proteins [3].
These functional pathways included acute-phase re-
sponse signalling (p = 2.93 × 10− 1), the complement
system (p = 2.11 × 10− 1) and liver X receptor/retinoic X
receptor signalling (p = 1.95 × 10− 1). Moreover, many
more functional pathways were affected as a result of
the proteins that were differentially abundant in
response to stage II compared with stage I in non-
responders compared with responders (Additional file 1:
Tables S1 and S2), reiterating that the SF proteomic re-
sponse to cartilage harvest is more distinct in non-
responders to ACI.
Similar pathways were identified from the differentially
abundant proteins identified in iTRAQ nLC-MS/MS and LF
LC-MS/MS analyses
Both iTRAQ nLC-MS/MS and LF LC-MS/MS analyses
resulted in acute-phase response signalling being
highlighted as one of the most significantly affected
pathways in response to cartilage harvest in non-
responders to ACI; therefore, this pathway was further
assessed. Figure 3 highlights that analysis of the SF
proteome using the two independent proteomic tech-
niques resulted in a greater number of differentially
abundant downstream proteins being identified. In
Table 3 Fold change of proteins that are differentially abundant in the synovial fluid of clinical non-responders compared with clinical re-
sponders to autologous chondrocyte implantation (ACI) immediately prior to stage II
Protein Fold Change Identification method
Description Accession LF LC-MS/MS iTRAQ nLC-MS/MS
40S Ribosomal protein S14 P62263 − 8.63 +
Kinectin Q86UP2 − 6.20 +
Apolipoprotein C-III P02656 − 2.78 +
High-mobility group protein B1 P09429 − 2.56 +
Kininogen-1 P01042 2.27 +
26S Protease regulatory subunit 7 P35998 2.34 +
26S Proteasome non-ATPase regulatory subunit 13 Q9UNM6 2.43 +
Alpha-enolase P06733 2.56 +
Alpha-2-HS-glycoprotein P02765 2.78 +
Hemopexin P02790 2.88 +
Ferritin light chain P02792 2.91 +
Platelet factor 4 P02776 3.26 +
Thrombospondin-1 P07996 3.40 +
Nucleosome assembly protein 1-like 1 P55209 4.94 +
Cofilin-1 P23528 7.08 +
EH domain-containing protein 1 Q9H4M9 7.30 +
Haemoglobin subunit delta P02042 8.09 +
Protein S100-A6 P06703 8.39 +
T-complex protein 1 subunit eta Q99832 8.43 +
Haemoglobin subunit beta P68871 32.81 +
Haemoglobin subunit alpha P69905 44.06 +
Footnote: Differential abundance was denoted by greater than or equal to ± 2.0-fold change; p ≤ 0.05; protein identified by at least two unique peptides. Positive
numbers denote higher abundance in non-responders than in responders. Proteins were identified using either protein dynamic compression coupled with label-free
quantitation LC-MS/MS or no protein dynamic compression with isobaric tags for absolute and relative quantitation (iTRAQ) LC-MS/MS
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addition, many complementary proteins have been iden-
tified when comparing these datasets, with the vast
majority of proteins that are predicted to be increased in
the plasma (the standard bodily fluid referred to in
Ingenuity Pathway Analysis) during the acute-phase re-
sponse being more abundant in the SF at stage II than at
stage I and vice versa.
Because the results of the two proteomic approaches
seem to be complementary to one another, the two datasets
were combined to generate a more comprehensive profile
of the SF proteome. Ingenuity Pathway Analysis again iden-
tified many functional pathways similar to those identified
via the independent LF LC-MS/MS and iTRAQ nLC-MS/
MS datasets. The most significant canonical pathways asso-
ciated with the non-responder response to cartilage harvest
(stage II versus stage I) were acute-phase response signal-
ling (p = 1.10 × 10− 9), intrinsic prothrombin activation
pathway (p = 3.43X10− 7) and the complement system (p =
Fig. 1 Biochemical validation of differentially abundant proteins identified using isobaric tagging for relative and absolute quantitation (iTRAQ)
proteomics. a and d Differential abundance of complement C1S subcomponent (C1S) and matrix metalloproteinase 2 as measured by iTRAQ MS
and biochemical enzyme-linked immunosorbent assay (ELISA), respectively. Quantitative ELISA confirmed that (b) C1S is significantly decreased in
the synovial fluid (SF) of non-responders (NR) compared with responders (R) to autologous chondrocyte implantation (ACI) prior to cartilage harvest
(stage I [S1]; p = 0.04 by Student’s t test) (c) but was not significantly differentially abundant prior to chondrocyte implantation (stage II [S2]).
Matrix metalloproteinase 3 (MMP3) (e) was not differentially abundant in response to cartilage harvest in ACI responders (f) but was biochemically
confirmed to be differentially abundant in the SF of non-responders between stages I and II of the ACI procedure (p = 0.001 by Student’s t test)
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Table 4 Fold change of proteins that are differentially abundant in the synovial fluid of clinical responders at stage II compared with
stage I of autologous chondrocyte implantation (ACI)
Protein Fold change Identification method
Description Accession no. LF LC-MS/MS iTRAQ nLC-MS/MS
Microtubule-associated protein 1B P46821 − 20.65 +
40S Ribosomal protein S14 P62263 − 16.75 +
Protein disulphide-isomerase A6 Q15084 − 7.59 +
Nucleolin P19338 − 5.11 +
Histone H1.2 P16403 − 3.84 +
Stress-induced-phosphoprotein 1 P31948 − 3.63 +
Complement factor D P00746 − 3.44 +
SH3 domain-binding glutamic acid-rich-like protein O75368 − 3.44 +
Heterogeneous nuclear ribonucleoprotein U Q00839 − 3.40 +
78 kDa Glucose-regulated protein P11021 − 3.25 +
Cartilage oligomeric matrix protein P49747 − 3.10 +
Annexin A2 P07335 − 2.96 +
Mesencephalic astrocyte-derived neurotrophic factor P55145 − 2.86 +
Kinectin Q86UP2 − 2.81 +
Complement factor H-related protein 3 Q02985 − 2.77 +
Phosphatidylethanolamine-binding protein 1 P30086 − 2.51 +
Peroxiredoxin-4 Q13162 − 2.49 +
Regucalcin Q15493 − 2.44 +
Malate dehydrogenase, mitochondrial P40926 − 2.44 +
N-acetylglucosamine-6-sulphatase P15586 − 2.31 +
Gelsolin P06396 − 2.27 +
Alpha-endosulfine O43768 − 2.25 +
Peptidyl-prolyl cis-trans isomerase FKBP3 Q00688 − 2.11 +
Hemopexin P02790 2.05 +
Serum paraoxonase/arylesterase 1 P27169 2.07 +
Secreted phosphoprotein 24 Q13103 2.10 +
Heparin cofactor 2 P05546 2.13 +
Ferritin light chain P02792 2.21 +
Attractin O75882 2.21 +
Ig gamma-2 chain C region P01859 2.23 +
Plasma kallikrein P03952 2.24 +
Chondroitin sulphate proteoglycan 4 Q6UVK1 2.35 +
Collagen alpha-2(I) chain P08123 2.37 +
Collagen alpha-1(V) chain P20908 2.54 +
CD5 antigen-like O43866 2.58 +
Phospholipid transfer protein P55058 2.63 +
Insulin-like growth factor-binding protein complex acid labile subunit P35858 2.68 +
Prothrombin P00734 2.68 +
Beta-2-glycoprotein 1 P02749 2.78 +
Collagen alpha-2(V) chain P05997 2.84 +
Plasma protease C1 inhibitor P05155 2.91 +
Serum amyloid P component P02743 2.91 +
Complement C1q subcomponent subunit B P02746 3.01 +
Collagen alpha-1(I) chain P02452 3.05 +
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Table 4 Fold change of proteins that are differentially abundant in the synovial fluid of clinical responders at stage II compared with
stage I of autologous chondrocyte implantation (ACI) (Continued)
Protein Fold change Identification method
Description Accession no. LF LC-MS/MS iTRAQ nLC-MS/MS
Alpha-2-antiplasmin P08697 3.10 +
Alpha-1B-glycoprotein P04217 3.19 +
Complement factor B P00751 3.25 +
Complement component C7 P10643 3.40 +
Vitamin K-dependent protein S P07225 3.42 +
Apolipoprotein E P02649 3.44 +
Alpha-1-antichymotrypsin P01011 3.44 +
Carboxypeptidase N subunit 2 P22792 3.53 +
Vitronectin P04004 3.63 +
Inter-alpha-trypsin inhibitor heavy chain H3 Q06033 3.66 +
Complement C5 O P01031 4.00 +
Plasminogen P00747 4.06 +
Kininogen 1 P01042 4.17 +
Platelet factor 4 P02776 4.26 +
Inter-alpha-trypsin inhibitor heavy chain H2 P19823 4.49 +
Periostin Q15063 4.57 +
Apolipoprotein L1 O14791 4.61 +
Protein 4.1 P11171 4.66 +
26S Proteasome non-ATPase regulatory subunit 13 Q9UNM6 4.78 +
Inter-alpha-trypsin inhibitor heavy chain H1 P19827 5.01 +
Inter-alpha-trypsin inhibitor heavy chain H4 Q14624 5.06 +
Complement C1r subcomponent P00736 5.15 +
Complement component C6 P13671 5.45 +
Complement factor H P08603 5.50 +
Catalase P04040 5.60 +
Ficolin-3 O75636 6.43 +
C4b-binding protein alpha chain P04003 7.05 +
Ceruloplasmin P00450 7.51 +
Pregnancy zone protein P20742 8.09 +
Fibrinogen alpha chain P02671 8.40 +
Apolipoprotein M O95445 9.04 +
Protein S100-A6 P06703 9.82 +
Haemoglobin subunit alpha P69905 9.82 +
Complement C1s subcomponent P09871 10.00 +
Ig mu chain C region P01871 12.13 +
Haptoglobin P00738 13.68 +
Fibrinogen beta chain P02675 16.90 +
Haemoglobin subunit beta P68871 19.41 +
Fibrinogen gamma chain P02679 23.55 +
Footnote: Differential abundance was denoted by greater than or equal to ± 2.0-fold change; p ≤ 0.05; protein identified by at least two unique
peptides. Positive numbers denote higher abundance at stage II than at stage I. Proteins were identified using either protein dynamic compression
coupled with label-free quantitation LC-MS/MS or no protein dynamic compression with isobaric tags for absolute and relative quantitation
(iTRAQ) LC-MS/MS
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Table 5 Fold change of proteins that are differentially abundant in the synovial fluid of clinical non-responders at stage II compared with
stage I
Protein Fold
change
Identification method
Description Accession LF LC-MS/MS iTRAQ nLC-MS/MS
Protein S100-A6 P06703 − 4.49 +
Annexin A1 P04083 − 4.13 +
Haemoglobin subunit beta P68871 − 4.09 +
Complement factor D P00746 − 3.87 +
Perilipin-4 Q96Q06 − 3.87 +
Gelsolin P06396 − 3.31 +
Gelsolin P06396 − 1.68 +
Syntaxin 7 O15400 − 3.31 +
Fermitin family homolog 3 Q86UX7 − 3.29 +
Histone H1.2 P16403 − 3.13 +
Transaldolase P37837 − 3.08 +
Neuroblast differentiation-associated protein AHNAK Q09666 − 2.78 +
Heterogeneous nuclear ribonucleoprotein K P61978 − 2.69 +
Hyaluronan and proteoglycan link protein 3 Q96S86 − 2.65 +
Alpha-enolase P06733 − 2.63 +
ATP-citrate synthase P53396 − 2.63 +
Annexin A2 P07355 − 2.56 +
Fatty acid-binding protein, epidermal Q01469 − 2.43 +
Peroxiredoxin-1 Q06830 − 2.20 +
Tripeptidyl-peptidase 1 O14773 − 2.19 +
Insulin-like growth factor-binding protein 6 P24592 − 2.13 +
Na+/H+ exchange regulatory cofactor NHE-RF1 O14745 − 2.11 +
Peroxiredoxin-6 P30041 − 2.08 +
Histamine N-methyltransferase P50135 − 2.07 +
Mortality factor 4-like protein 1 Q9UBU8 − 2.06 +
Transcription elongation factor A protein 1 P23193 − 2.06 +
Cartilage acidic protein 1 Q9NQ79 − 2.03 +
2′,3′-cyclic-nucleotide 3′-phosphodiesterase P09543 − 1.20 +
Fructose-bisphosphate aldolase A P04075 − 1.97 +
Leucine zipper transcription factor-like protein 1 Q9NQ48 − 1.94 +
Protein S100-A13 Q99584 − 1.94 +
40S Ribosomal protein S3 P23396 − 1.93 +
Filamin-A P21333 − 1.92 +
Microtubule-associated protein RP/EB family member 1 Q15691 − 1.92 +
Nuclear migration protein nudC Q9Y266 − 1.90 +
Prostaglandin E synthase 3 Q15185 − 1.85 +
Stress-induced phosphoprotein 1 P31948 − 1.85 +
Cytokine-like protein 1 Q9NRR1 − 1.81 +
Plastin-2 P13796 − 1.81 +
Coronin-1C Q9ULV4 − 1.80 +
Vinculin P18206 − 1.80 +
Cathepsin K P43235 − 1.79 +
Hsc70-interacting protein P50502;Q8IZP2 − 1.76 +
Putative phospholipase B-like 2 Q8NHP8 − 1.74 +
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Table 5 Fold change of proteins that are differentially abundant in the synovial fluid of clinical non-responders at stage II compared with
stage I (Continued)
Protein Fold
change
Identification method
Description Accession LF LC-MS/MS iTRAQ nLC-MS/MS
Spectrin beta chain, erythrocytic P11277 − 1.73 +
Complement factor I P05156 2.11 +
Alpha-1-antichymotrypsin P01011 2.22 +
Titin Q8WZ42 2.23 +
Cytoplasmic dynein 1 heavy chain 1 Q14204 2.23 +
F-actin-capping protein subunit beta P47756 2.25 +
Mannan-binding lectin serine protease 1 P48740 2.26 +
Serum amyloid P-component P02743 2.27 +
Complement component C6 P13671 2.29 +
Thrombospondin-3 P49746 2.36 +
Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D A1L4H1 2.39 +
Plasma kallikrein P03952 2.42 +
Complement factor B P00751 2.47 +
Afamin P43652 2.47 +
Vitamin K-dependent protein S P07225 2.49 +
Vitamin K-dependent protein S P07225 3.08 +
Integrin beta-like protein 1 O95965 2.51 +
C4b-binding protein beta chain P20851 2.55 +
Fibronectin P02751 2.58 +
Clusterin P10909 2.65 +
Vitronectin P04004 2.68 +
Bifunctional glutamate/proline-transfer RNA ligase P07814 2.70 +
Nucleobindin 1 Q02818 2.71 +
Complement component C9 P02748 2.75 +
Zinc-alpha-2-glycoprotein P25311 2.75 +
Complement C1r subcomponent P00736 2.83 +
Heparin cofactor 2 P05546 2.83 +
Ferritin light chain P02792 2.84 +
Proteoglycan 4 Q92954 2.88 +
C4b-binding protein alpha chain P04003 2.91 +
C4b-binding protein alpha chain P04003 10.38 +
Matrix metalloproteinase 3 P08254 2.91 +
Attractin O75882 2.94 +
Insulin-like growth factor-binding protein complex acid labile subunit P35858 3.02 +
Alpha-1B-glycoprotein P04217 3.05 +
Fibrinogen alpha chain P02671 3.10 +
Fibrinogen alpha chain P02671 11.91 +
Lumican P51884 3.13 +
Chondroitin sulphate proteoglycan 4 Q6UVK1 3.16 +
Collagen alpha-2(V) chain P05997 3.19 +
Complement C2 P06681 3.22 +
Fibrinogen beta chain P02675 3.25 +
Fibrinogen beta chain P02675 18.37 +
Secreted phosphoprotein 24 Q13103 3.26 +
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1.22 × 10− 6). Further, analysis of upstream regulators to
these dysregulated proteins included those identified using
the LF LC-MS/MS analysis data alone, such as transform-
ing growth factor-β1 (p = 2.05 × 10− 13), dihydrotestosterone
(p = 4.48 × 10− 11) and peroxisome proliferator-activated
receptor-α (p = 1.09 × 10− 9) [3].
The combined datasets were then used to generate un-
biased interactome networks that represent the differen-
tially abundant proteins (non-inferred networks), their
likely interacting proteins (inferred networks) and how
these proteins interact with one another, resulting in
models of systemic protein response to cartilage harvest
in either the responders or non-responders to ACI.
Based on proteins that were differentially abundant be-
tween stages I and II of ACI in non-responders, an inter-
actome network consisting of 115 nodes (proteins) and
40 edges (protein-protein interactions) was generated.
Further, an inferred network consisting of 2893 proteins
and 35,576 protein-protein interactions was generated
on the basis of the addition of proteins that are likely to
Table 5 Fold change of proteins that are differentially abundant in the synovial fluid of clinical non-responders at stage II compared with
stage I (Continued)
Protein Fold
change
Identification method
Description Accession LF LC-MS/MS iTRAQ nLC-MS/MS
Matrix metalloproteinase 1 P03956 3.33 +
Latent-transforming growth factor beta-binding protein 1 Q14766 3.45 +
Phospholipid transfer protein P55058 3.47 +
Inter-alpha-trypsin inhibitor heavy chain H3 Q06033 3.47 +
Complement C1q tumour necrosis factor-related protein 3 Q9BXJ4 3.50 +
Adipocyte enhancer-binding protein 1 Q8IUX7;Q8N436 3.51 +
Adiponectin Q15848 3.52 +
Fibrinogen gamma chain P02679 3.79 +
Fibrinogen gamma chain P02679 18.37 +
Plasminogen P00747 3.84 +
Apolipoprotein C-II P02655 3.94 +
CD5 antigen-like O43866 4.17 +
Collagen alpha-1(V) chain P20908 4.26 +
Complement factor H P08603 4.57 +
Inter-alpha-trypsin inhibitor heavy chain H4 Q14624 4.61 +
Complement C5 P01031 4.74 +
Collagen alpha-1(I) chain P02452 4.84 +
Ceruloplasmin P00450 5.01 +
Histidine-rich glycoprotein P04196 5.11 +
Target of Nesh-SH3 Q7Z7G0 5.25 +
Plasma protease C1 inhibitor P05155 5.30 +
Apolipoprotein M O95445 5.65 +
Inter-alpha-trypsin inhibitor heavy chain H2 P19823 5.70 +
Periostin Q15063 5.81 +
Apolipoprotein C-III P02656 5.92 +
Kinectin Q86UP2 6.02 +
Carboxypeptidase N subunit 2 P22792 7.73 +
Serum paraoxonase/arylesterase 1 P27169 8.02 +
Apolipoprotein L1 O14791 8.95 +
Ig mu chain C region P01871 13.30 +
Apolipoprotein E P02649 13.80 +
Inter-alpha-trypsin inhibitor heavy chain H1 P19827 15.56 +
Footnote: Differential abundance was denoted by greater than or equal to ± 2.0-fold change; p ≤ 0.05; protein identified by at least two unique
peptides. Positive numbers denote higher abundance at stage II compared with stage I of autologous chondrocyte implantation (ACI). Proteins were
identified using either protein dynamic compression coupled with label free quantitation LC-MS/MS or no protein dynamic compression with isobaric
tags for absolute and relative quantitation (iTRAQ) LC-MS/MS. Proteins identified by both proteomic techniques are underlined and in italics
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interact with the differentially abundant proteins
(PINA4MS interactome database). Proteins that were
differentially abundant in response to cartilage harvest
in responders to ACI were used to generate interactome
networks (non-inferred, 83 nodes and 118 edges; in-
ferred, 2084 nodes and 54,007 edges). The ModuLand
algorithm was applied to each of these networks to iden-
tify modules within the network that can be hierarchic-
ally ranked to identify groups of proteins that are the
most fundamental in the functioning of the network.
Figure 4 highlights the top ten modules from each of the
networks generated. These modules again highlight the
disparity between the ACI responder and non-responder
response to cartilage harvest, with only modules centred
on the proto-oncogene tyrosine-protein kinase (Src) pro-
tein being identified in the inferred networks of both
non-responder and responder groups. Interestingly, as-
sessment of the functional pathways related to the
ModuLand identified modules in the non-responder net-
works again highlighted regulation of the complement
cascade (p = 1.68 × 10− 8 by Fisher’s exact test), thus
providing confidence in its importance based on
identification via two independent bioinformatics
approaches.
Discussion
On the basis of its recent technology appraisal of ACI,
NICE has recommended this treatment for a specific
subset of patients with cartilage injury in the knee [2].
The identification of novel biomarkers that can
strengthen current patient demographic risk factors in
predicting clinical outcomes [9], as well as development
of a greater understanding of the underlying biology as-
sociated with success and failure, will be beneficial,
particularly because this treatment option is likely to be
implemented on a wider scale in the near future. The
present study builds upon our previously published work
[3, 8], highlighting a number of novel protein candidates
that have potential as biomarkers to predict ACI out-
come. Moreover, comprehensive proteomic profiling of
SF has further highlighted proteomic differences be-
tween responders and non-responders to ACI.
In the majority of studies in which the SF proteome
has been profiled, either high-abundance proteins
[11–16] or low-abundance proteins [17–22] have been
assessed via depletion or non-depletion of abundant
proteins prior to proteomic analysis. Our study high-
lights that the use of both a proteomic dynamic range
compression technique (ProteoMiner™) [3] in tandem
with analysis of non-depleted SF samples can provide
a more holistic overview of proteomic changes, be-
cause both iTRAQ nLC-MS/MS and LF LC-MS/MS
highlighted large numbers of differentially abundant
proteins between stages I and II of ACI, with little
crossover between techniques. This type of all-
inclusive approach to unbiased whole-proteome
analysis of biological fluids may therefore be more
successful in the identification of candidate bio-
markers for treatments/disease states beyond those we
investigated.
A limitation of our previous study [3] was that very
few proteins were identified as differentially abundant
between responders and non-responders at baseline. In
order for biomarkers aimed at predicting ACI success to
be most clinically useful, patients who are likely to fail
or respond to this procedure need to be identified prior
to any surgical intervention. Interestingly, analysis of
non-dynamic range compressed proteins with iTRAQ
Fig. 2 Venn diagrams representing the proteins identified using isobaric tags for relative and absolute quantitation (iTRAQ) proteomics and label-
free quantitation (LF) proteomics. The proteins shown were differentially abundant (≥ 2.0-fold change; p≤ 0.05) in the SF at stage I (SI) compared
with stage II (SII) in responders (R) compared with non-responders (NR) to ACI
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nLC-MS/MS analysis was able to detect a greater num-
ber of differentially abundant proteins between re-
sponders and non-responders prior to stage I surgery.
The protein with most altered abundance in responders
compared with non-responders at stage I was C1s. This
higher abundance in responders was confirmed in indi-
vidual patient samples using a biochemical assay. C1s is
a major constituent of the trimeric complement C1 pro-
tein, which triggers the classical complement pathway.
Once activated, the classical complement pathway pro-
motes inflammation to enable the removal of damaged
cells and/or microbes. Moreover, C1s has been shown to
cleave insulin-like growth factor 1 (IGF-1) [45] and
insulin-like growth factor binding protein 5 (IGFBP-5)
[46]. Both IGF-1 and IGFBP-5 are chondroprotective
when in their intact state [45, 47], and inhibition of C1s
activity within the canine SF reduced cleavage of IGFBP-
5 and IGF-1, resulting in reduced cartilage damage fol-
lowing anterior cruciate ligament rupture [45]. These
studies indicate that high C1s activity levels are likely
detrimental to cartilage repair. Further, the complement
cascade is known to be important in the pathogenesis of
OA, with patients with OA demonstrating increased
gene expression of complement agonists compared to
inhibitors [48]. OA-related pathogenesis, such as the re-
lease of cartilage extracellular matrix molecules and the
production of inflammatory mediators, induces comple-
ment activation [48]. The increased pre-operative levels
that we identified in individuals who responded well to
ACI perhaps indicate that ACI has potential to be suc-
cessful in individuals who may have developed an early
OA phenotype.
Analysis of the iTRAQ nLC-MS/MS and LF LC-MS/
MS datasets, both independently and when combined,
highlighted that there is a marked proteomic shift in re-
sponse to cartilage harvest (i.e., between stages I and II
of ACI). This analysis resulted in a plethora of candidate
biomarkers that may have the potential to be informative
regarding whether an individual is likely to respond well
to ACI prior to chondrocytes being implanted during
stage II. The proteoglycan, collagens II-, IX- and X-
degrading enzyme, MMP3 [49] has been biochemically
Fig. 3 Proteins of acute-phase signalling at stage II compared with stage I in non-responders to autologous chondrocyte implantation (ACI). Sev-
eral synovial fluid proteins that are downstream of acute-phase response signalling were differentially abundant between stages I and II of ACI.
Proteins edged in purple, orange and blue were identified using isobaric tagging for relative and absolute quantitation (iTRAQ) nano LC-MS/MS,
label-free quantitation (LF) LC-MS/MS or both techniques, respectively. (Adapted from Ingenuity Pathway Analysis.)
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validated as one of these candidate proteins that is sig-
nificantly increased at stage II compared with stage I
only in non-responders to ACI. Use of these biomarkers
could have the potential to prevent the burden of a sec-
ond surgery in a patient for whom this therapy is likely
to be unsuccessful and could indicate that a greater
period of time should be left from when the cartilage
harvest procedure takes place to when the cells are im-
planted or that a tailored cartilage implantation proced-
ure would be more efficacious.
To investigate the significant proteome shift that exists
in response to cartilage harvest, pathway analyses were
performed to better distinguish the underlying biological
mechanisms that dictate whether an individual will re-
spond to ACI. The acute-phase response was the path-
way predicted to be most significantly differentially
regulated in response to cartilage harvest in non-
responders to ACI. In-depth assessment of individual
protein changes within this pathway again highlighted
the benefit of using independent proteomic techniques
to profile the SF, because a large number of proteins
were differentially abundant between stages I and II,
only three of which were identified using both tech-
niques. The acute-phase response is the body’s first sys-
temic response to immunological stress, trauma and
surgery [50]. At the site of injury/trauma, pro-
inflammatory cytokines are normally released, activating
inflammatory cells and ultimately resulting in inflamma-
tory mediators and cytokines being released into the
extracellular fluid compartment to be circulated in the
blood [50]. Interestingly, previous bioinformatics ana-
lyses of the proteome of patients with late OA compared
with healthy control subjects highlighted a dysregulated
acute-phase response in the end-stage OA cohort [18].
The exacerbated activation of the acute-phase response
in non-responders following initial surgery could indi-
cate that these patients have a greater immune response
to surgery and that they have a lesser ability to dampen
the acute-phase following surgery or that they have
already developed an advanced OA phenotype, deeming
a therapy to repair cartilage injury unsuitable.
Finally, the datasets of combined iTRAQ nLC-MS/MS
and LF LC-MS/MS identified proteins were used to gen-
erate interactome models that represent the systemic
proteomic response to cartilage harvest which exists
within the SF of both ACI responders and non-
responders, from which biological functional pathways
could be further studied. Biological functional pathways
that were identified using this approach, as well as using
Ingenuity Pathway Analysis can most confidently be
taken forward as candidates for further study because
they have been identified by independent bioinformatic
methods. Furthermore, given the complexity of the knee
joint environment, it is likely that the responder/non-re-
sponder phenotype is the result of many subtle protein
changes which together contribute to overall dysfunction
of a biological network, rather than being the result of
an individual biological molecule or pathway per se.
Therefore, the interactome models generated in this
study provide an important opportunity to consider how
these proteins interact with one another and result in
such phenotypes, and they also provide a platform for
further studies to investigate how potential modifications
to the ACI procedure (e.g., using co-incidental anti-
inflammatory drugs in non-responders at stage II) may
alter these biological networks. Thus, these models may
provide a potential in silico tool for predicting ACI out-
come, as is commonly used in drug development strat-
egies [51].
Conclusions
This study highlights the advantage of using two inde-
pendent proteomic techniques to profile a holistic
overview of the SF proteome, ideal for unbiased identifi-
cation of biomarker candidates. iTRAQ nLC-MS/MS
Fig. 4 The ModuLand algorithm was applied in Cytoscape to
inferred and non-inferred interactome networks of differentially
abundant proteins (± 1.2-fold change; p≤ 0.05) between stages I
and II of autologous chondrocyte implantation in clinical responders
and non-responders. Modules were identified from both non-inferred
(protein changes identified from proteomic analysis only) and inferred
(identified protein changes and inferred proteins interactions) networks
and are ranked on the basis of their hierarchical network connectivity
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analysis of SF samples from individuals who have either
responded well or very poorly to ACI has highlighted
proteins that, with further validation, have the potential
to predict clinical outcome prior to treatment. We have
confirmed that there is a marked SF proteome shift
following cartilage injury, which is exacerbated in non-
responders. Network and pathway analyses have demon-
strated the complexity of the biological response under-
lying this proteome shift in non-responders, with several
biological pathways identified that may act as targets for
therapeutic intervention.
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Additional file 1: Table S1. Canonical pathways altered in the synovial
fluid of clinical nonresponders at stage I compared with stage II of ACI,
identified using Ingenuity Pathway Analysis based on proteins that were
identified using iTRAQ proteomics (≥ 1.2-fold change). Significance was
assessed using a right-sided Fisher’s exact test; therefore, the most significant
canonical pathways represent those that are the least likely to have been
identified because of molecules being in the canonical pathway by random
chance. The z-score represents canonical pathways that are likely activated or
inhibited (based on the pattern of differentially abundant proteins); NaN
means no prediction could be made based on the number of differentially
abundant proteins in the pathway. Table S2. Canonical pathways altered in
the synovial fluid of clinical responders at stage I compared with stage II of
ACI, identified using Ingenuity Pathway Analysis, based on proteins which
were identified using iTRAQ proteomics (≥ 1.2-fold change). Significance was
assessed using a right-sided Fisher’s exact test; therefore, the most significant
canonical pathways represent those that are the least likely to have been
identified because of molecules being in the canonical pathway by random
chance. The z-score represents canonical pathways that are likely activated or
inhibited (based on the pattern of differentially abundant proteins); NaN
means no prediction could be made based on the number of differentially
abundant proteins in the pathway. (XLSX 19 kb)
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